UniQure NV (QURE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

UniQure NV (QURE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH389133D
  • |
  • Pages: 73
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

UniQure NV (UniQure) formerly uniQure BV is a pharmaceutical company that develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies by using its modular technology platform. Its glybera is used to restore the LPL enzyme activity. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia B, sanfilippo B syndrome, acute intermittent porphyria, congestive heart failure and Parkinson's disease. UniQure is also developing gene therapies for cardiovascular diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.

UniQure NV (QURE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

UniQure NV, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

uniQure Raises Additional USD10 Million in Venture Debt Financing 12

uniQure Raises US$10 Million In Venture Financing 12

UniQure Raises USD17.5 Million in Venture Financing 13

Partnerships 14

Bristol-Myers Squibb Enters into Agreement with uniQure 14

Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 15

uniQure Enters Into Co-Marketing Agreement With Chiesi Farmaceutici 16

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 17

Amsterdam Molecular Therapeutics Enters Into An Agreement With Institut Pasteur And The Consortium 18

Licensing Agreements 19

uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19

uniQure Enters into Licensing Agreement with Protein Sciences 20

Treeway Enters into Licensing Agreement with uniQure 21

uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology 21

Benitec Biopharma Enters Into Licenising Agreement With uniQure 22

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 23

Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 24

Equity Offering 25

uniQure Raises USD38 Million in Private Placement of Shares 25

uniQure Raises USD88.5 Million in Public Offering of Shares 26

uniQure Completes IPO For US$91.8 Million 27

uniQure Announces Private Placement Of Shares For US$7.8 Million 29

Acquisition 30

UniQure Acquires InoCard for USD4 Million 30

uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 31

UniQure NV-Key Competitors 33

Key Employees 34

Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 36

Financial Announcements 36

May 09, 2017: uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress 36

Mar 15, 2017: uniQure Announces 2016 Financial Results and Provides Update on Company Progress 38

Jan 25, 2017: uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs 40

Nov 22, 2016: uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress 41

Aug 25, 2016: uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress 43

May 31, 2016: uniQure Announces Results for First Quarter 2016 45

Apr 04, 2016: uniQure Announces Results for Fourth Quarter and Financial Year 2015 47

Corporate Communications 49

Dec 19, 2016: uniQure Appoints Matthew Kapusta as Chief Executive Officer 49

Sep 22, 2016: uniQure Announces Management and Board Changes 50

Sep 16, 2016: uniQure Receives NASDAQ Deficiency Letter Related to Board Composition 51

Jul 07, 2016: uniQure Appoints Jonathan Garen as Chief Business Officer 52

May 09, 2016: uniQure Announces the Nomination of Jack Kaye to its Board of Directors and Proposed Corporate Governance Changes 53

May 03, 2016: uniQure Appoints Paul Firuta as Chief Commercial Officer 54

Product News 55

12/03/2016: uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B 55

11/03/2016: uniQure Announces Upcoming Presentation of Data at Annual American Society of Hematology Meeting 57

07/27/2016: uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect 58

07/11/2016: uniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress 60

06/11/2016: uniQure Presents Clinical Data from Ongoing Phase I/II Study in Hemophilia B Demonstrating 6 Months of Sustained Increases in Factor IX Activity 61

05/19/2016: uniQure Announces Oral Presentation of Clinical Data from Ongoing Phase I/II Study of AMT-060 in Hemophilia B at the 21st Congress of the European Hematology Association 63

04/24/2017: uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy 64

04/04/2017: uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System 65

02/06/2017: uniQure Announces Presentations at Upcoming February Conferences 66

Product Approvals 67

Apr 25, 2017: uniQure Receives European Medicines Agency Priority Medicines Designation for AMT-060 in Hemophilia B 67

Jan 30, 2017: uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B 68

Clinical Trials 69

May 10, 2017: uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates 69

Apr 26, 2017: uniQure Presents New Preclinical Data on AMT-130 in Huntington's Disease at CHDI's 12th Annual Huntington's Disease Therapeutics Conference 70

Mar 22, 2016: uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington's Disease 71

Other Significant Developments 72

Jan 09, 2017: uniQure Outlines Key Initiatives for 2017 and Vision for 2018 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73

List of Figures

UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

UniQure NV, Pharmaceuticals & Healthcare, Key Facts, 2015 1

UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

UniQure NV, Deals By Therapy Area, 2011 to YTD 2017 9

UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

uniQure Raises Additional USD10 Million in Venture Debt Financing 12

uniQure Raises US$10 Million In Venture Financing 12

UniQure Raises USD17.5 Million in Venture Financing 13

Bristol-Myers Squibb Enters into Agreement with uniQure 14

Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 15

uniQure Enters Into Co-Marketing Agreement With Chiesi Farmaceutici 16

uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 17

Amsterdam Molecular Therapeutics Enters Into An Agreement With Institut Pasteur And The Consortium 18

uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19

uniQure Enters into Licensing Agreement with Protein Sciences 20

Treeway Enters into Licensing Agreement with uniQure 21

uniQure Enters Into Licensing Agreement With Benitec Biopharma For RNA Interference Technology 21

Benitec Biopharma Enters Into Licenising Agreement With uniQure 22

uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 23

Amsterdam Molecular Expands Licensing Agreement With National Institutes Of Health 24

uniQure Raises USD38 Million in Private Placement of Shares 25

uniQure Raises USD88.5 Million in Public Offering of Shares 26

uniQure Completes IPO For US$91.8 Million 27

uniQure Announces Private Placement Of Shares For US$7.8 Million 29

UniQure Acquires InoCard for USD4 Million 30

uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 31

UniQure NV, Key Competitors 33

UniQure NV, Key Employees 34

UniQure NV, Other Locations 35

UniQure NV, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

UniQure NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16190
Site License
USD 500 INR 32380
Corporate User License
USD 750 INR 48570

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com